Pharmacogenetics to Avoid Adverse Drug Reactions
Pharmacogenetics to Avoid Adverse Drug Reactions
English[eng]
9783040000000
5-fluorouracil||capecitabine||fluoropyrimidine||thymidylate synthase||thymidylate synthase enhancer region||upstream stimulatory factor 1||adverse drug reactions||pharmacogenomics||epistasis||random forest||statin||cardiovascular disease||colorectal cancer||personalised medicine||toxicity||(es)citalopram||drug-gene-interaction||drug-drug-interaction||drug-drug-gene-interaction||the PharmLines initiative||antipsychotic agents||pharmacogenetics||cytochrome P-450 enzyme system||psychotic disorders||precision medicine||direct oral anticoagulants||clinical implementation||atorvastatin||SLCO1B1||HLA||cutaneous adverse drug reaction||SCAR||genetic polymorphism||antiepileptics||CYP450 enzymes||platelet reactivity||single-nucleotide variants||acute coronary syndrome||clopidogrel||genotype||allele||polymorphism||HLA B||CYP2C9*3||cutaneous adverse drug reactions (CADRs)||anti-epileptic drugs (AEDS)||phenytoin (PHT)||genetic risk factors||South India||India||cardiology||adverse events||guidelines||n/a
English[eng]
9783040000000
5-fluorouracil||capecitabine||fluoropyrimidine||thymidylate synthase||thymidylate synthase enhancer region||upstream stimulatory factor 1||adverse drug reactions||pharmacogenomics||epistasis||random forest||statin||cardiovascular disease||colorectal cancer||personalised medicine||toxicity||(es)citalopram||drug-gene-interaction||drug-drug-interaction||drug-drug-gene-interaction||the PharmLines initiative||antipsychotic agents||pharmacogenetics||cytochrome P-450 enzyme system||psychotic disorders||precision medicine||direct oral anticoagulants||clinical implementation||atorvastatin||SLCO1B1||HLA||cutaneous adverse drug reaction||SCAR||genetic polymorphism||antiepileptics||CYP450 enzymes||platelet reactivity||single-nucleotide variants||acute coronary syndrome||clopidogrel||genotype||allele||polymorphism||HLA B||CYP2C9*3||cutaneous adverse drug reactions (CADRs)||anti-epileptic drugs (AEDS)||phenytoin (PHT)||genetic risk factors||South India||India||cardiology||adverse events||guidelines||n/a